FDA Approves Durvalumab for Advanced Endometrial Cancer Treatment
Source-Oncologynewscentral.com On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s drug Durvalumab (IMFINZI®) for the treatment of primary advanced or recurrent endometrial cancer in patients with mismatch repair deficiency. Endometrial cancer is recognized as the most common gynecologic cancer in the United States, with an estimated 66,200 new cases in 2023 alone. The FDA’s approval underscores the growing importance of immune checkpoint inhibitors, particularly those targeting PD-L1, in the fight against cancer. PD-L1, or programmed death-ligand 1, is a protein that plays a crucial role in helping tumors evade the immune system. By blocking this protein, drugs like Durvalumab can enhance the immune system’s ability to recognize and attack cancer cells, potentially leading to improved treatment outcomes for patients. This approval not only highlights the effectiveness of such therapies but also represents a significant advancement in the ongoing effort...